

# A significant response to neoadjuvant chemotherapy in *BRCA1/2* related breast cancer

P O Chappuis, J Goffin, N Wong, C Perret, P Ghadirian, P N Tonin, W D Foulkes

*J Med Genet* 2002;39:608–610

Neoadjuvant (preoperative) chemotherapy was initially developed as a first line treatment for locally advanced breast cancer. More recently, it has been used to treat earlier stage operable disease, with the hope that not only could the treatment be used as an *in vivo* assessment of tumour response, but also that it might more readily eradicate occult distant micrometastases. Many studies have shown a small but significant increase in breast conservation when neoadjuvant chemotherapy was used but, overall, most randomised studies have not shown any survival advantage following this treatment.<sup>1,2</sup> Despite this, it has been noted that women receiving neoadjuvant chemotherapy who experience either a clinical complete response (cCR) ( $\leq 40\%$  of all those treated) or, more clearly, a pathological complete response (pCR) ( $\leq 10\%$ ) have a better long term outcome than women who achieve less than a complete response.<sup>1,2</sup>

Germline mutations in the *BRCA1* and *BRCA2* genes are the major genetic predisposition to breast cancer. Some of the functions of *BRCA1* and *BRCA2* proteins could be directly involved in response to cytotoxic agents, such as the role of *BRCA1/2* in DNA repair<sup>3</sup> or apoptosis.<sup>4,5</sup> Distinct pathological features<sup>6</sup> and gene expression profiles<sup>7</sup> suggest that there are differences in hereditary breast cancer compared to sporadic cases, which might lead to differences in treatment response. *In vitro* data suggest that cells without functional *BRCA1* or *BRCA2* protein are particularly sensitive to several chemotherapeutic drugs<sup>4</sup> or ionising radiation.<sup>8</sup> Mouse and human cell lines deficient in *BRCA1* or *BRCA2* display an increased sensitivity to agents causing double strand DNA breaks.<sup>9,10</sup> This hypersensitivity has been shown for mitoxantrone, amsacrine, etoposide, doxorubicin, and cisplatin with a subsequent increased level of apoptosis.<sup>9,11–13</sup> Differences in drug sensitivity might be explained by interaction of *BRCA1/2* proteins with various pathways leading to apoptosis.<sup>13,14</sup> These findings raise the question of the efficacy of adjuvant chemotherapy or hormone therapy for breast cancer among women who carry a germline *BRCA1/2* mutation.

## MATERIAL AND METHODS

To address the question of initial response to chemotherapy for hereditary breast cancer, we reviewed all cases of Ashkenazi Jewish (AJ) or French Canadian (FC) women treated with neoadjuvant chemotherapy and for whom founder *BRCA1/2* mutation status had been determined through genetic testing facilities in Montreal, QC. We have a clinicopathological database of 615 AJ or FC women who have been tested for the known founder mutations in *BRCA1/2* that are present in these two populations.<sup>15,16</sup> This testing was performed in both clinical and research settings between 1995 and 2001. By comparing this database with one containing women treated by neoadjuvant chemotherapy at McGill University or Université de Montréal hospitals, we identified 38 women (seven *BRCA1* mutation carriers (hereafter “carriers”), four *BRCA2* carriers, and 27 non-carriers) who developed histologically or cytologically diagnosed primary breast cancer

(stages I–III) and received neoadjuvant treatment. Not carrying a germline *BRCA1/2* mutation was defined as follows: (1) for Ashkenazi Jewish patients ( $n=12$ ), absence of the three *BRCA1/2* founder mutations<sup>15</sup>; and (2) for patients of French Canadian origin ( $n=15$ ), absence of seven *BRCA1/2* founder mutations<sup>16</sup> as well as a BRCAPRO score of  $<2\%$ . One woman (J007) was identified as a *BRCA1* carrier 13 months before developing breast cancer and another (AJ32) was identified as a *BRCA1/2* non-carrier 17 months before her diagnosis. In all other cases, genetic testing was performed at or after breast cancer diagnosis. The period of time that elapsed between breast cancer diagnosis and genetic testing was not statistically different among *BRCA1/2* carriers and non-carriers (median 0.5 year *v* 0.3 year, respectively,  $p=0.84$ , Mann-Whitney U test).

The full clinicopathological details of the 38 subjects are shown in supplementary tables 1 and 2 ([www.jmedgenet.com](http://www.jmedgenet.com)). Twenty-six out of 38 patients (6/11 carriers and 20/27 non-carriers,  $p=0.28$ ) were included in prospective multi-centre clinical trials that evaluated neoadjuvant treatment in breast cancer (NSABP-B18, -B26, and -B27, NCIC MA.10). Except for one patient (AJ32) treated with paclitaxel alone, all patients received anthracycline based chemotherapy (usually four cycles) before surgery. After neoadjuvant treatment, all except two patients (1236 and 98120) underwent either a lumpectomy or segmental mastectomy with axillary lymph node dissection or a modified radical mastectomy. Clinical response was defined as: (1) complete response (CR), no residual palpable disease; (2) partial response (PR),  $\geq 50\%$  reduction in bidimensional measurements of the breast mass and axillary adenopathy; (3) no change, between 50% reduction and 25% increase in tumour size; or (4) progressive disease,  $>25\%$  increase in tumour size. As various regimens of neoadjuvant chemotherapy were administered, clinical response was systematically evaluated after three or four cycles of chemotherapy, and further clinical responses after any subsequent cycles were not included in any of our analyses (for full details, see supplementary tables 1 and 2). Pathological complete response (pCR) was recorded when there was no evidence of residual tumour cells in the breast and axillary lymph nodes. For the other cases, the pathological response was considered incomplete. No patient showed residual non-invasive (*in situ*) tumour cells without invasive component.

## RESULTS

No significant difference was noted between carriers and non-carriers for age at diagnosis (mean (median) 44.1, SD 8.4 (43.4) years *v* 47.6, SD 11.4 (46.2) years,  $p=0.37$ ), tumour size (mean (median) 5.5, SD 2.6 (6.0) cm *v* 4.9, SD 3.0 (4.0) cm,

**Abbreviations:** AJ, Ashkenazi Jewish; FC, French Canadian; cCR, clinical complete response; pCR, pathological complete response; CR, complete response; PR, partial response; ER, oestrogen receptor

**Table 1** (A) Clinical and (B) pathological responses to neoadjuvant chemotherapy in *BRCA1/2* carriers and non-carriers

A	Clinical complete response	Less than clinical complete response	p value
<i>BRCA1/2</i> carriers	10	1	–
Non-carriers			
Unmatched	8	19	0.0009
Matched*	2	9	0.002
B	Pathological complete response	Less than pathological complete response	p value
<i>BRCA1/2</i> carriers†	4	5	–
Non-carriers			
Unmatched	1	26	0.009
Matched*	0	9	0.08

\*Carriers were matched to controls on TNM stage and on closest age (means 44.1 and 44.3 years,  $p=0.95$ ) and grade.  
†Two carriers who had a clinical complete response were excluded from this analysis because they did not have any further surgery after neoadjuvant chemotherapy.

$p=0.52$ ), oestrogen receptor (ER) status ( $p=0.23$ ), or tumour grade (mean (median) 2.6, SD 0.50 (3) v 2.4, SD 0.76 (3),  $p=0.44$ ) (supplementary tables 1 and 2). After three or four cycles of neoadjuvant chemotherapy, a cCR was recorded in 10 of 11 *BRCA1/2* carriers (93%) compared with eight of 27 non-carriers (30%),  $p=0.0009$  (table 1A). Notably, four (two *BRCA1* carriers and two *BRCA2* carriers) of nine (44%) evaluable *BRCA1/2* carriers had no residual tumour in the breast and the axillary lymph nodes (pCR), whereas only one case of pCR (4%) was noted among the non-carriers ( $p=0.009$ , table 1B). When we matched the cases 1:1 to controls on precise TNM stage, the significance of the effect of mutation status on complete clinical response rate was slightly less marked (table 1A), reflecting the smaller sample size. Similarly, when we analysed pCR in the matched series of 18 carriers and non-carriers, the effect diminished and is of borderline statistical significance (table 1B).

## DISCUSSION

We report here preliminary evidence for a differential response to neoadjuvant chemotherapy for breast cancer on the basis of germline *BRCA1/2* mutation status. *BRCA1/2* carriers showed a better clinical response rate to neoadjuvant chemotherapy than did non-carriers. Importantly, the clinical and pathological responses to neoadjuvant treatment observed in *BRCA1/2* non-carriers were concordant with what has been reported previously.<sup>1</sup> The probability of a CR appears to be independent of clinical stage<sup>17,18</sup> and here we found that the four pCRs seen among the carriers were distributed in all initial stages (supplementary table 1).

We recognise that this study has several limitations. In particular, this is a very small series of patients who were identified through established research and clinical protocols for *BRCA1/2* mutation analysis, and the criteria for testing differed from study to study and over time. As such, and because of a clinic based selection, there is a possibility of bias. The most important bias would be a survival bias, but we have shown that this can be excluded, as there were no important differences in the time intervals between breast cancer diagnosis and *BRCA1/2* mutation testing when comparing carriers and non-carriers. As this is not a prospective (incident) cohort study, we did not have the opportunity to study women who received neoadjuvant chemotherapy, but died before testing could be offered. If a substantial proportion of such women were *BRCA1/2* carriers, we may have overestimated the response rates in carriers.

One might expect that the breast cancers occurring in our series of carriers would have different clinicopathological features than those seen in non-carriers, as these differences are

well known.<sup>6</sup> In the unmatched analyses, we did not observe significant differences for age at diagnosis, ER status, or tumour grade among carriers and non-carriers, although some non-significant differences were noted. It is possible that the small sample size and the younger than expected age of the controls accounts for this finding. Whatever the reason for the lack of difference, the clinicopathological characteristics of the breast cancers occurring in carriers and non-carriers, whether matched or unmatched, suggests that such potential differences are unlikely to explain the results we observed, particularly as a statistically significant difference in clinical response rates was observed when close matching was performed.

Another possibility is that pCR was preferentially achieved by carriers because they received more chemotherapy before pathological confirmation of response. However, only one carrier with pCR received more than four cycles of neoadjuvant chemotherapy, and this woman (J322, supplementary table 1) had achieved a cCR after four cycles of doxorubicin and cyclophosphamide. Moreover, five non-carriers (supplementary table 2) received more than four cycles of neoadjuvant chemotherapy without achieving a pCR, so it does not appear that adding further chemotherapy after the fourth cycle is the reason why, overall, carriers were statistically significantly more likely to achieve pCR than were non-carriers.

As stated above, the breast cancers occurring in *BRCA1/2* carriers and non-carriers did not significantly differ in terms of standard clinicopathological variables. It is therefore tempting to speculate that it is the presence of the germline *BRCA1/2* mutation per se that is determining the difference in response to neoadjuvant chemotherapy.

Considering outcome, women who have a cCR and/or pCR have a better long term outcome than women who do not achieve a CR.<sup>2,17,19,20</sup> Presumably, those who achieve CR are more likely to have eliminated micrometastases. We and others previously showed that *BRCA1/2* mutation status is associated with a worse outcome after invasive breast cancer.<sup>21–23</sup> This apparent paradox of a very good initial response to preoperative chemotherapy among carriers and a worse long term survival needs further study. Of note, no survival studies have been stratified according to the administration of adjuvant chemotherapy. Among a cohort of 292 Ashkenazi Jewish women diagnosed with invasive breast cancer between 1980 and 1995, we recently showed that the overall survival was significantly worse among *BRCA1* mutation carriers compared to non-carriers, but only among patients who did not receive adjuvant chemotherapy.<sup>24</sup> Putting our two observations together, one might speculate that the poor survival observed in some retrospective series is partly explained by the omission of chemotherapy in these historical series, and that

this might have been ameliorated by adjuvant chemotherapy. Therefore, as little is known about the in vivo response of *BRCA1/2* related breast cancer to chemotherapeutic agents, it will be important to establish whether the very promising initial response to neoadjuvant chemotherapy we observed in *BRCA1/2* carriers will be sustained. Larger, prospective studies will be required to confirm or refute our preliminary observations.

## ACKNOWLEDGEMENTS

We thank Ann-Josée Paradis, Nancy Hamel, Karlene Australie, Lidia Kasprzak, and Muna Al-Saffar for technical assistance. POC was funded by a fonds de perfectionnement of the University Hospital of Geneva, Geneva, Switzerland. PNT is a recipient of a Fraser, Monat and McPherson Scholarship and the Stewart Fellowship in Research/Clinical Hematology and Oncology. WDF is a recipient of a Fonds de Recherche en Santé du Québec (FRSQ) Clinician Scientist J2 Fellowship. This work was supported in part by grants from the Department of Defence (No DAMD17-98-1-8112), the FRSQ (FRSQ-Réseau cancer: Axe Cancer du Sein et de l'Ovaire), the Canadian Breast Cancer Foundation, the CURE foundation, and the Canadian Genetic Diseases Network.

## Authors' affiliations

**P O Chappuis\***, Division of Medical Genetics, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada

**J Goffin**, Department of Oncology, McGill University, Montreal, Quebec, Canada

**N Wong**, Cancer Prevention Research Unit and Department of Medicine, Sir M B Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada

**C Perret, P Ghadirian**, Epidemiology Research Unit, Research Centre, CHUM-Hôtel-Dieu, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada

**P N Tonin, W D Foulkes**, Program in Cancer Genetics, Departments of Oncology and Human Genetics, Research Institute of the McGill University Health Centre and Department of Medicine, McGill University, Montreal, Quebec, Canada

Correspondence to: Dr W D Foulkes, Montreal General Hospital/Room L10-120, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada; william.foulkes@mcgill.ca

\*Present address: Divisions of Oncology and Medical Genetics, University Hospital, Geneva, Switzerland.

## REFERENCES

- 1 **Wolff AC**, Davidson NE. Primary systemic therapy in operable breast cancer. *J Clin Oncol* 2000;**18**:1558-69.
- 2 **van Der Hage JA**, van De Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902. *J Clin Oncol* 2001;**19**:4224-37.
- 3 **Scully R**, Livingston DM. In search of the tumour-suppressor functions of *BRCA1* and *BRCA2*. *Nature* 2000;**408**:429-32.
- 4 **Thangaraju M**, Kaufmann SH, Couch FJ. *BRCA1* facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. *J Biol Chem* 2000;**275**:33487-96.
- 5 **Xu X**, Qiao W, Linke SP, Cao L, Li WM, Furth PA, Harris CC, Deng CX. Genetic interactions between tumour suppressors *Brcal* and *p53* in apoptosis, cell cycle and tumorigenesis. *Nat Genet* 2001;**28**:266-71.
- 6 **Lakhani SR**, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Easton DF. Multifactorial analysis of differences between sporadic breast cancers and cancers involving *BRCA1* and *BRCA2* mutations. *J Natl Cancer Inst* 1998;**90**:1138-45.
- 7 **Hedenfalk I**, Duggan D, Chen Y, Radmacher M, Bitner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J. Gene-expression profiles in hereditary breast cancer. *N Engl J Med* 2001;**344**:539-48.
- 8 **Sharan SK**, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A. Embryonic lethality and radiation hypersensitivity mediated by *Rad51* in mice lacking *Brc2*. *Nature* 1997;**386**:804-10.

- 9 **Abbott DW**, Freeman ML, Holt JT. Double-strand break repair deficiency and radiation sensitivity in *BRCA2* mutant cancer cells. *J Natl Cancer Inst* 1998;**90**:978-85.
- 10 **Khanna KK**, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. *Nat Genet* 2001;**27**:247-54.
- 11 **Husain A**, He G, Venkatraman ES, Spriggs DR. *BRCA1* up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). *Cancer Res* 1998;**58**:1120-3.
- 12 **Bhattacharyya A**, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene *BRCA1* is required for subnuclear assembly of *Rad51* and survival following treatment with the DNA cross-linking agent cisplatin. *J Biol Chem* 2000;**275**:23899-903.
- 13 **Ren Q**, Potoczek MB, Krajewski S, Krajewska M, Basu A, Haldar S, Reed JC, Turner BC. Transcriptional regulation of the *Bcl-2* gene by wild type *BRCA1* is important in regulating response to DNA damage-induced apoptosis [abstract]. *Proc Am Assoc Cancer Res* 2001;**42**:2991.
- 14 **Freneaux P**, Stoppa-Lyonnet D, Mouret E, Kambouchner M, Nicolas A, Zafrani B, Vincent-Salomon A, Fourquet A, Magdelenat H, Sastre-Garau X. Low expression of *bcl-2* in *Brc1*-associated breast cancers. *Br J Cancer* 2000;**83**:1318-22.
- 15 **Tonin P**, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalas J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Kraimer M, Haber DA, Struwing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Lynch HT, Lenoir GM, Narod SA, Garber JE. Frequency of recurrent *BRCA1* and *BRCA2* mutations in Ashkenazi Jewish breast cancer families. *Nat Med* 1996;**2**:1183-96.
- 16 **Tonin PN**, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P, Narod SA. Founder *BRCA1* and *BRCA2* mutations in French Canadian breast and ovarian cancer families. *Am J Hum Genet* 1998;**63**:1341-51.
- 17 **Kuerer HM**, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. *J Clin Oncol* 1999;**17**:460-9.
- 18 **Buchholz TA**, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, Frye D, Strom EA, McNeese MD, Perkins G, Katz A, Singletary SE, Hunt KK, Buzdar AU, Hortobagyi GN. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. *J Clin Oncol* 2002;**20**:17-23.
- 19 **Fisher B**, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. *J Clin Oncol* 1998;**16**:2672-85.
- 20 **Chang J**, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. *J Clin Oncol* 1999;**17**:3058-63.
- 21 **Robson M**, Levin D, Federici M, Satagopan J, Bogolmyn F, Heerdt A, Borgen P, McCormick B, Hudis C, Norton L, Boyd J, Offit K. Breast conservation therapy for invasive breast cancer in Ashkenazi women with *BRCA* gene founder mutations. *J Natl Cancer Inst* 1999;**91**:2112-17.
- 22 **Chappuis PO**, Kapusta L, Bégin LR, Wong N, Brunet JS, Narod SA, Slingerland J, Foulkes WD. Germline *BRCA1/2* mutations and *p27(Kip1)* protein levels independently predict outcome after breast cancer. *J Clin Oncol* 2000;**18**:4045-52.
- 23 **Stoppa-Lyonnet D**, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Boursstyn E, Clough KB, Magdelenat H, Pouillart P, Vincent-Salomon A, Fourquet A, for the Institute Curie Breast Cancer Group, and Asselian B. Familial invasive breast cancer: worse outcome related to *BRCA1* mutations. *J Clin Oncol* 2000;**18**:4053-9.
- 24 **Chappuis PO**, Goffin J, Hamel N, Wong N, Paradis AJ, Roberge D, Brunet JS, Yee C, Tonin P, Boyd J, Ghadirian P, Bégin LR, Foulkes WD. Good response to chemotherapy (CT) and hormone therapy (HT) in patients with *BRCA1*-related breast cancer (*BRCA1-BC*) (abstract). *Am J Hum Genet Suppl* 2001;**69**:249.



Supplementary tables 1 and 2 can be found on the journal website at [www.jmedgenet.com](http://www.jmedgenet.com)